[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)].
This article reviews the theoretical background, the sometimes severe side effects and the possible clinical implications of treatments with monoclonal anti-T cell antibodies in Multiple Sclerosis (MS). We conclude that there is no indication for treatment with monoclonal anti-T cell antibodies at the present time, except in controlled trials.